🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Spain / NCT06213402
Recruiting Observational

RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs)

NCT06213402 · tracked via the Priya Life Science Spain tracker
Phase
Observational
Started
2021-11-30
Last updated
2024-01-19

Condition(s) studied

Sickle Cell DiseaseThalassemiaHemolytic; Anemia, Hereditary, Due to Enzyme DisorderAnemia Due to Membrane DefectCDASideroblastic AnemiaConstitutional Aplastic AnemiaIron Metabolism DisordersHereditary Anemia

Investigational drug(s) / intervention(s)

Data collection from EHR.

Data collection from EHR.: Collection of clinical and laboratory data. Reviwe of the electronic health record

Study summary

Rare Anaemia Disorders (RADs) is a group of rare diseases characterized for presenting anaemia as the main clinical manifestation. Different medical entities classified as RADs by ORPHA classification are most of them chronic life threating disorders with many unmet needs for their proper clinical management creating an impact on European health systems. RADs present diagnostic challenges and their appropriate management requires from specialised multidisciplinary teams in Centers of expertise.

Although there are some examples of well-established national registries on RADs in EU, the lack of recommendations for Rare disease registries implementation and the lack of standards for interoperability has led to the fragmentation or unavailability of data on prevalence, survival, main clinical manifestations or treatments in most of the European countries.

Eligibility

Sex
ALL
Min age
0 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria: * Patients must meet all of the following criteria to be included in the RADeep Registry * Age from 0-100, both female and male * Diagnosed as RADs (SCD, THAL, PKD, and other RADs THAL according to ORPHANET classification) * Able and willing to provide written informed consent (patient or legal representative for minors) Exclusion Criteria: * Patient or legal representative for minors unwilling or unable to give consent * Patients diagnosed with SCD or THAL (alpha-thalassaemia and beta-thalassaemia) traits or trait conditions for other recessive RADs

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Vall d'hebron Research Institute - Vall d'Hebron Research Institute - University Hospital Vall d'Hebrón (VHIR/HUVH) Barcelona Catalonia Recruiting

More Hospital Universitari Vall d'Hebron Research Institute trials in Spain

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06213402 on ClinicalTrials.gov ↗ ← All trials in Spain